GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » ROC %

Zylox-Tonbridge Medical Technology Co (HKSE:02190) ROC % : 3.52% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zylox-Tonbridge Medical Technology Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 3.52%.

As of today (2025-03-26), Zylox-Tonbridge Medical Technology Co's WACC % is 9.44%. Zylox-Tonbridge Medical Technology Co's ROC % is 2.50% (calculated using TTM income statement data). Zylox-Tonbridge Medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Zylox-Tonbridge Medical Technology Co ROC % Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co ROC % Chart

Zylox-Tonbridge Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial -82.01 -116.40 -29.12 -9.52 3.11

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -35.00 -12.01 -7.68 3.52 1.41

Zylox-Tonbridge Medical Technology Co ROC % Calculation

Zylox-Tonbridge Medical Technology Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-157.979 * ( 1 - 0% )/( (1414.177 + 1905.818)/ 2 )
=-157.979/1659.9975
=-9.52 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3633.45 - 141.434 - ( 2077.839 - max(0, 169.834 - 2303.335+2077.839))
=1414.177

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3692.27 - 255.82 - ( 1652.557 - max(0, 347.584 - 1878.216+1652.557))
=1905.818

Zylox-Tonbridge Medical Technology Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=75.754 * ( 1 - 0% )/( (1905.818 + 2396.825)/ 2 )
=75.754/2151.3215
=3.52 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3692.27 - 255.82 - ( 1652.557 - max(0, 347.584 - 1878.216+1652.557))
=1905.818

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3753.362 - 257.21 - ( 1259.578 - max(0, 386.054 - 1485.381+1259.578))
=2396.825

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zylox-Tonbridge Medical Technology Co  (HKSE:02190) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zylox-Tonbridge Medical Technology Co's WACC % is 9.44%. Zylox-Tonbridge Medical Technology Co's ROC % is 2.50% (calculated using TTM income statement data). Zylox-Tonbridge Medical Technology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zylox-Tonbridge Medical Technology Co ROC % Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zylox-Tonbridge Medical Technology Co Business Description

Traded in Other Exchanges
Address
270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).
Executives
Wang Stephen Hui 2201 Interest of corporation controlled by you
Hang Zhou Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo 2401 A concert party to an agreement to buy shares
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2401 A concert party to an agreement to buy shares
Wea Enterprises, Llc 2401 A concert party to an agreement to buy shares
Zhong Shengping Sam 2401 A concert party to an agreement to buy shares
Zhao Jonathon Zhong 2501 Other
Wei Na 2501 Other
Li Zheng 2501 Other
Schroders Plc 2102 Investment manager
Ourea Biotech Hk Limited 2501 Other
Highlight Medical Limited 2501 Other
Five Investment Limited 2501 Other

Zylox-Tonbridge Medical Technology Co Headlines

No Headlines